| CASE REPORT |
|
| Year : 2022 | Volume
: 9
| Issue : 4 | Page : 145-148 |
|
|
Durable response of immune checkpoint inhibitor for a patient with advanced gastric adenosquamous carcinoma
Cheng-Lun Lai1, Ming-Huang Chen2
1 Division of Hematology/Medical Oncology, Department of Medicine, Taichung Veterans General Hospital, Taichung, Taiwan
2 Department of Oncology, Center of Immuno-Oncology, Taipei Veterans General Hospital; School of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan
Correspondence Address:
Dr. Cheng-Lun Lai
Division of Hematology/Medical Oncology, Department of Medicine, Taichung Veterans General Hospital, 1650 Taiwan Boulevard Sect. 4, Taichung
Taiwan
 Source of Support: None, Conflict of Interest: None
DOI: 10.4103/2311-3006.362634
|
|
|
Gastric adenosquamous carcinoma (GASC) is an extremely rare malignancy of the stomach. It is generally diagnosed at an advanced stage and is associated with a poor prognosis. Notably, the standard treatments for GASC remain undetermined because of the condition's rarity. In this report, we present a patient diagnosed with advanced GASC with positive predictive biomarkers for immune checkpoint inhibitors (ICIs), who achieved a durable response through nivolumab monotherapy. We also review and discuss the management of GASC and possible roles of ICIs in gastric cancers.
|
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
